Heliyon (Oct 2024)

Bioactivities and industrial standardization status of Ganoderma lucidum: A comprehensive review

  • Peng Wu,
  • Chengyun Zhang,
  • Yueyue Yin,
  • Xiaobin Zhang,
  • Qi Li,
  • Lijingyi Yuan,
  • Yahe Sun,
  • Shuhua Zhou,
  • Shanting Ying,
  • Jiayan Wu

Journal volume & issue
Vol. 10, no. 19
p. e36987

Abstract

Read online

Ganoderma lucidum (GL) is a potent source of bioactive compounds with diverse nutritional and pharmacological benefits. Its popularity as a dietary supplement, herbal remedy, and wellness product is steadily on the rise. Furthermore, the standardized advancement of the GL industry has facilitated reliable sourcing of raw materials and quality control measures, enhancing its utilization and endorsement in the realms of nutritional science and pharmaceutical research. This article provides a comprehensive overview of the recent advancements in research pertaining to the bioactive components of GL, particularly polysaccharides (GLP) and triterpenes (GLTs) as well as highlights the latest findings regarding their beneficial effects on human diseases, including anticancer, antidiabetes, liver protection and other aspects (such as regulating gut microbiota, antioxidant, antimicrobial, antiinflammatory and immune regulation). Furthermore, we summarized the potential applications of GL in the food and pharmaceutical sectors, while also examining the current status of standardization throughout the entire industrial chain of GL, both domestically and internationally. These information offer an insight and guidance for the prospects of industrial development and the innovative advancement of GL within the global health industry.

Keywords